Aflibercept vs Ranibizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Ranibizumab · Lucentis

Marketed by Roche and partners

Approved in Age-Related Macular Degenerationantibody fragment
Partial signal

NCT00056836 · Phase 3 · completed

The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.

Reported efficacy

Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.

Result source: NCT00056836

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Aflibercept: 20 of 20 rows · Ranibizumab: 20 of 20 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAflibercept
Rows use multiple source trials
Ranibizumab
Rows use multiple source trials
BCVA (20/40
responder rate · % of participants
41% (n=39) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
47.5% (n=40) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
26.3% (n=38) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
41% (n=39) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
47.5% (n=40) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
26.3% (n=38) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
BCVA 20/40
absolute value · percentage points
No placebo or comparator arm
52.5% (n=40) @ 52wkc,d,e
NCT01950741 · Phase 4 · registry result, not featured evidence
46.2% (n=275) @ 52wk0.5 mg as-needed (PRN)a,c,d,e
NCT00891735 · Phase 3 · registry result, not featured evidence
show 3 more doses
52.4% (n=275) @ 52wk0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
43.6% (n=273) @ 52wk2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
50% (n=274) @ 52wk2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
BCVA Change Letters
absolute change · letters
3.63 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
4.22 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
-3.17 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
3.63 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
4.22 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
-3.17 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
BCVA Change Letters
absolute change · Letters correctly read
No placebo or comparator arm
10.8 Letters correctly read @ 52wka,c,d,e
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
10.7 Letters correctly read @ 52wk
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
1 Letters correctly read @ 52wk0.5 mga,c,d,e
NCT01780935 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.1 Letters correctly read @ 52wk0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
BCVA Change Letters
absolute change · letters
No placebo or comparator arm
9 letters @ 52wka,b,e
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more dose
8.4 letters @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
12.3 letters @ 52wk0.5 mg monthlya,b,e
NCT01775124 · Phase 4 · registry result, not featured evidence
show 1 more dose
9.6 letters @ 52wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
BCVA Change Letters
absolute change · Letters
No placebo or comparator arm
10.8 Letters @ 52wka,b
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
10.7 Letters @ 52wk
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
5.1 Letters @ 52wk0.5 mga,b
NCT01846273 · Phase 4 · registry result, not featured evidence
show 1 more dose
8.3 Letters @ 52wk0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
BCVA Gain 15 Letters
absolute value · percentage points
37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4a,f,b,e,g
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more doses
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
39.1% (n=151) vs 34% (n=147) Lucentis @ 24wk1.5 mg / 0.5 mga,f,b,e,g
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
33.3% (n=147) vs 34% (n=147) Lucentis @ 24wk0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
BCVA Loss Less Than 15 Letters
responder rate · % of participants
98.7% (n=228) vs 92.1% (n=76) PDT @ 28wkb,e,h
NCT01482910 · Phase 3 · registry result, not featured evidence
94.6% vs 62.2% sham @ 51.96wkRanibizumab 0.5 mga,b,e,h
NCT00056836 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
94.5% vs 62.2% sham @ 51.96wkRanibizumab 0.3 mg
NCT00056836 · Phase 3 · sponsor-reported, not registry data
CNV Area Change Mm2
absolute change · mm
-4.71 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
-4.91 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.02 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
-4.71 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
-4.91 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.02 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
Complete Polyp Regression
event count · % of participants
No placebo or comparator arm
38.5% (n=13) @ 52wk*a,b
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
show 1 more dose
53.8% (n=39) @ 52wk*
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 21 Participants as posted
33.8% (n=154) @ 52wk*0.5 mga,b
NCT01846273 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted
show 1 more dose
68.5% (n=168) @ 52wk*0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination · converted to % from 115 Participants as posted
CRT Change Microns
absolute change · m
No placebo or comparator arm
-134.4 m @ 52wka,b,e
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more dose
-126.1 m @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
-147.1 m @ 52wka,b,e
NCT01972789 · Phase 4 · registry result, not featured evidence
show 1 more dose
-125.6 m @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
CST Change Microns
absolute change · m
-46.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
-72.4 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
12.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
-46.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk4.0 mg iSONEPa,b
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
-72.4 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
12.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
Lesion Area Change Mm2
absolute change · mm
-4.7 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,i,b,e,j
NCT02713204 · Phase 2 · registry result, not featured evidence
show 2 more doses
-3.9 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
-5.3 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
-0.6382 vs -1.1814 Lucentis mm @ 48wki,b,e,j
NCT02611778 · Phase 3 · registry result, not featured evidence
NEI VFQ-25 Total
absolute change · score
6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4a,b,e,k
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more doses
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.3 vs 3.75 Lucentis score @ 48wkb,e,k
NCT02611778 · Phase 3 · registry result, not featured evidence
NEI VFQ-25 Total
absolute change · score
No placebo or comparator arm
7.3 score @ 52wka,c,b,e
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
4.7 score @ 52wk
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
2.3 score @ 52wk0.5 mg treat-and-extenda,c,b,e
NCT01948830 · Phase 3 · registry result, not featured evidence
show 1 more dose
4 score @ 52wk0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
no IRF and no SRF Center Subfield
event count · % of participants
No placebo or comparator arm
50.9% (n=53) @ 16wk*l,b,e,m
NCT04126317 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
37.2% (n=172) @ 104wk*a,l,b,e,m
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 64 Participants as posted
show 1 more dose
32.4% (n=173) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted
Dropout rate
3.6%2.0mg Q4n
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
4.9%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%
NCT03022292 · Phase 4 · registry result, not featured evidence
6.1%
NCT02689518 · Phase 4 · registry result, not featured evidence
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
100%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
8.7%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
12.7%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
6.3%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.2%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
6.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
23.6%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
10.7%o
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
23%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
13.1%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
23%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
17.1%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
4.8%Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
17.3%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
6.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
6%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
20.4%
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
9.1%50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
20%Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
20%Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
5%
NCT02611778 · Phase 3 · registry result, not featured evidence
10%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
30%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
—
NCT02698566 · Phase 3 · registry result, not featured evidence
10.2%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
9.8%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
4.4%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
6.2%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
5.5%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
5.8%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
22.2%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
11.3%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
19.5%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
11.7%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
10.4%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
8.3%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
20%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
25%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
12.5%
NCT01914159 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
0%Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
8.3%Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
3.3%1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
3.4%0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
1%2.0mg Q4n
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
20%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
2.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
3.2%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—
NCT01950741 · Phase 4 · registry result, not featured evidence
—2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
2.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
3.2%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
1.9%o
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
6.2%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
5.4%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
6.3%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
2.3%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
4.8%Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
1.2%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
3%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
3%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
—
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
—50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
—Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
—Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
0.4%
NCT02611778 · Phase 3 · registry result, not featured evidence
10%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
10%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
—
NCT02698566 · Phase 3 · registry result, not featured evidence
2.8%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
0.6%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
0.6%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
5.6%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
5.8%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
10.2%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
3.3%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
4.3%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
—0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—
NCT01914159 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
—Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
—Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
23%2.0mg Q4n
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
26.7%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
15.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
17.2%Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
2.1%
NCT01950741 · Phase 4 · registry result, not featured evidence
20%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
2.3%Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
5.7%Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
4.2%PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
45.9%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
10%o
NCT02161575 · Phase 4 · registry result, not featured evidence
show 51 more results
17%0.5 mg
NCT01846273 · Phase 4 · registry result, not featured evidence
15.7%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
14.3%0.5 mg + vPDT
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
33.5%Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
—Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
33.3%Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
28.6%0.5 mg
NCT02140411 · Phase 4 · registry result, not featured evidence
—Ranibizumab
NCT02140411 · Phase 4 · registry result, not featured evidence
6.7%0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
—Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
4.1%
NCT01810042 · Phase 4 · registry result, not featured evidence
—
NCT01464723 · Phase 4 · registry result, not featured evidence
0%50% Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
20%Ranibizumab
NCT00473642 · Phase 4 · registry result, not featured evidence
0%Standard Fluence PDT
NCT00473642 · Phase 4 · registry result, not featured evidence · combination
8%
NCT02611778 · Phase 3 · registry result, not featured evidence
35%0.5 mg monthly
NCT01748292 · Phase 3 · registry result, not featured evidence
57.5%0.5 mg treat-and-extend
NCT01748292 · Phase 3 · registry result, not featured evidence
0%
NCT02698566 · Phase 3 · registry result, not featured evidence
12.1%0.5 mg treat-and-extend
NCT01948830 · Phase 3 · registry result, not featured evidence
12.9%0.5 mg monthly
NCT01948830 · Phase 3 · registry result, not featured evidence
9%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
13.4%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
20.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
24.1%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
19.9%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
19.7%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
22.2%Ranibizumab ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
15.6%Ranibizumab Non-ANCHOR
NCT00331864 · Phase 3 · registry result, not featured evidence
19.5%0.5 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
12.5%0.3 mg - 3 Times Monthly, Then Quarterly
NCT00275821 · Phase 3 · registry result, not featured evidence
17.4%0.3 mg Monthly
NCT00275821 · Phase 3 · registry result, not featured evidence
0%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
8%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
14.3%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01914159 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
0%Ranibizumab Group 1
NCT00896779 · Phase 2 · registry result, not featured evidence
0%Ranibizumab Group 2
NCT00896779 · Phase 2 · registry result, not featured evidence
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
6.6%high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
9.4%low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
2.0mg Q4n
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 39 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
drop in visual acuity 7.7%
punctate epithelial erosion 7.7%
raised blood pressure 7.7%
NCT03117634 · Phase 4 · registry result, not featured evidence
drop in vision due to cataract 5.1%
drop in visual acuity 5.1%
peri-orbital oedema (extra-ocular) 2.6%
NCT03117634 · Phase 4 · registry result, not featured evidence
myelodysplastic syndrome 3.8%
pneumonia 3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
hypertension 13.3%
depression 6.7%
ocular hypertension 6.7%
NCT02120950 · Phase 4 · registry result, not featured evidence
viral upper respiratory tract infection 11.2%
hypertension 8.1%
dry eye 6.8%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
viral upper respiratory tract infection 15.9%
conjunctival haemorrhage 6.4%
vitreous floaters 5.7%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
conjunctival hemorrhage 8.5%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.0 mg
cataract progression 6.7%
geographic atrophy progression 6.7%
NCT01543568 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
conjunctival haemorrhage 6%
macular fibrosis 2.8%
retinal pigment epitheliopathy 2.8%
NCT01482910 · Phase 3 · registry result, not featured evidence
macular fibrosis 11.8%
visual acuity reduced 7%
conjunctival haemorrhage 6.1%
NCT01482910 · Phase 3 · registry result, not featured evidence
visual acuity reduced 7%
conjunctival haemorrhage 5.6%
intraocular pressure increased 1.4%
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
2mg
fall 18.5%
hypertension 16.6%
nasopharyngitis 16.6%
NCT00527423 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
o
nasopharyngitis 9%
cough 7%
lower respiratory tract infection 7%
NCT02161575 · Phase 4 · registry result, not featured evidence
show 38 more results
0.5 mg
nasopharyngitis 7.4%
dizziness 3.7%
hypertension 3.7%
NCT01846273 · Phase 4 · registry result, not featured evidence
0.5 mg + vPDT
nasopharyngitis 13.4%
retinal haemorrhage (study eye) 7%
upper respiratory tract infection 7%
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
0.5 mg + vPDT
intraocular pressure increased (study eye) 28.6%
cerumen impaction 14.3%
fasciitis 14.3%
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
eye pain 16.2%
influenza 15%
influenza(non-ocular) 15%
NCT01972789 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.7%
nasopharyngitis(non-ocular) 16.7%
eye pain 13.8%
NCT01972789 · Phase 4 · registry result, not featured evidence
0.5 mg
oedema peripheral 19%
back pain 9.5%
bronchitis 9.5%
NCT02140411 · Phase 4 · registry result, not featured evidence
0.5 mg
neovascular age-related macular degeneration 3.6%
influenza 1.6%
conjunctival haemorrhage 1.4%
NCT01986907 · Phase 4 · registry result, not featured evidence
0.5 mg monthly
nasopharyngitis 14.5%
conjunctival haemorrhage 12.7%
upper respiratory tract infection 8.4%
NCT01775124 · Phase 4 · registry result, not featured evidence
0.5 mg PRN
nasopharyngitis 10.8%
conjunctival haemorrhage 7.2%
intraocular pressure increased 7.2%
NCT01775124 · Phase 4 · registry result, not featured evidence
neovascular age-related macular degeneration 8%
conjunctival haemorrhage 5.9%
nasopharyngitis 5%
NCT02611778 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
hollenhorst plaque 5%
subretinal hemorrhage 5%
progressive macular atrophy 0%
NCT01748292 · Phase 3 · registry result, not featured evidence
0.5 mg treat-and-extend
progressive macular atrophy 7.5%
subretinal hemorrhage 2.5%
hollenhorst plaque 0%
NCT01748292 · Phase 3 · registry result, not featured evidence
conjunctival hemorrhage 2.9%
NCT02698566 · Phase 3 · registry result, not featured evidence
0.5 mg treat-and-extend
intraocular pressure increased (study eye) 8.4%
hypertension 7.1%
nasopharyngitis 5.6%
NCT01948830 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
intraocular pressure increased (study eye) 8.6%
nasopharyngitis 8%
conjunctival haemorrhage (study eye) 5.8%
NCT01948830 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 7.2%
conjunctival haemorrhage (study eye) 5.7%
hypertension 5.4%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg
intraocular pressure increased (study eye) 6.3%
hypertension 4.5%
influenza 4.5%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg as-needed (PRN)
conjunctival haemorrhage 17.5%
sinusitis 9.8%
hypertension 7.6%
NCT00891735 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
conjunctival haemorrhage 23%
vitreous floaters 9.5%
vitreous detachment 8%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg as-needed (PRN)
conjunctival haemorrhage 15.1%
vitreous detachment 9.9%
eye pain 8.5%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg monthly
conjunctival haemorrhage 18.6%
eye pain 9.1%
vitreous detachment 8.8%
NCT00891735 · Phase 3 · registry result, not featured evidence
retinal haemorrhage (study eye) 27.8%
choroidal neovascularisation (fellow eye) 11.1%
choroidal neovascularisation (study eye) 11.1%
NCT00331864 · Phase 3 · registry result, not featured evidence
visual acuity reduced (study eye) 18.3%
intraocular pressure increased (study eye) 7%
retinal haemorrhage (study eye) 6.8%
NCT00331864 · Phase 3 · registry result, not featured evidence
0.5 mg - 3 Times Monthly, Then Quarterly
conjunctival haemorrhage (study eye) 16.1%
visual acuity reduced (study eye) 16.1%
eye pain (study eye) 11.9%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.3 mg - 3 Times Monthly, Then Quarterly
conjunctival haemorrhage (study eye) 19.2%
eye pain (study eye) 18.3%
visual acuity reduced (study eye) 12.5%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.3 mg Monthly
eye pain (study eye) 20.9%
intraocular pressure increased (study eye) 14.8%
conjunctival haemorrhage (study eye) 10.4%
NCT00275821 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
injection site irritation 4.5%
corneal abrasion 0%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0.5 mg PRN
corneal abrasion 4%
injection site irritation 4%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
4.0 mg
conjunctival hyperaemia 14.3% (placebo 0%)
eyelid oedema 10.7% (placebo 0%)
retinal haemorrhage 10.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
2.0 mg
eye pain 12.9% (placebo 0%)
conjunctival haemorrhage 9.7% (placebo 11.8%)
retinal haemorrhage 9.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
increase of subretinal hemorrhage 4.2%
NCT01914159 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
bruised sturnum 12.5%
development of choroidal neovascularization - fellow eye 12.5%
intestinal flu 12.5%
NCT00896779 · Phase 2 · registry result, not featured evidence
ache left eye - treatment eye 8.3%
cold 8.3%
corneal abrasion - both eyes 8.3%
NCT00896779 · Phase 2 · registry result, not featured evidence
high dose
conjunctival hemorrhage 33.6%
punctate keratitis 9.9%
conjunctival hyperemia 8.6%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
low dose
conjunctival hemorrhage 22.8%
punctate keratitis 12.8%
eye pain 6.7%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTrial phases differ: Phase 4 versus Phase 3.
  4. dPopulation context differs: registered conditions differ.
  5. eTreatment context has not been resolved for both arms.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gAssessment timepoints differ: 52 weeks versus 24 weeks.
  8. hAssessment timepoints differ: 28 weeks versus 51.96 weeks.
  9. iTrial phases differ: Phase 2 versus Phase 3.
  10. jAssessment timepoints differ: 36 weeks versus 48 weeks.
  11. kAssessment timepoints differ: 52 weeks versus 48 weeks.
  12. lTrial phases differ: Phase 2 versus Phase 4.
  13. mAssessment timepoints differ: 16 weeks versus 104 weeks.
  14. nPopulation comparability has not been reviewed for 39 of these studies.
  15. oPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14 vs 3.9 PDT Letters correctly read @ 28wk
NCT01482910 · Phase 3 · registry result, not featured evidence
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 8.1 ETDRS Letters @ 52wk
absolute change · ETDRS Letters
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 ETDRS Letters @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
CST Change Microns -248.8 um @ 52wk
absolute change · um
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
-164.8 um @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
BCVA Letters 0.3 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.33 score @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
CST Change Microns 0.08 ratio @ 24wk
ratio to baseline · ratio
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.07 ratio @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
PED Thickness Change Microns 0.26 ratio @ 24wk
ratio to baseline · ratio
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.38 ratio @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
BCVA Loss Less Than 15 Letters 93.4% (n=106) @ 104wk2 mg intravitreal
responder rate · % of participants
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 5 more results
96.2% (n=104) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=106) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=104) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
97.5% (n=157) @ 52wk
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
96.9% (n=161) @ 52wk
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
BCVA Change Letters 7.8 Letters @ 52wk2 mg intravitreal
absolute change · Letters
No placebo or comparator arm
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
10.2 Letters @ 52wk2 mg intravitreal
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence

+ 47 further endpoints in the CSV export.

Ranibizumab

Dry Retina Resolution 0% (n=100) @ 25.7wk
event count · % of participants
No placebo or comparator arm
Day 180 · Yes, Definitive
NCT02161575 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
Complete Polyp Regression 30.4% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
71.3% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
22% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Complete Polyp Regression 26.7% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
56.6% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
47.5% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 73.5% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
43% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
78% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 26.5% (n=113) @ 26wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
55.1% (n=168) @ 26wk0.5 mg + vPDT
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
22% (n=41) @ 26wk0.5 mg + vPDT
Month 6 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 72.6% (n=113) @ 52wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
47.7% (n=168) @ 52wk0.5 mg + vPDT
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
80.5% (n=41) @ 52wk0.5 mg + vPDT
Month 12 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 27.4% (n=113) @ 52wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
51.6% (n=168) @ 52wk0.5 mg + vPDT
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
19.5% (n=41) @ 52wk0.5 mg + vPDT
Month 12 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Active CNV Leakage 65.1% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
56.8% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
56.1% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - Yes
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
Absence of Leakage 34.9% (n=113) @ 104wk0.5 mg
responder rate · % of participants
No placebo or comparator arm
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
40.4% (n=168) @ 104wk0.5 mg + vPDT
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
39% (n=41) @ 104wk0.5 mg + vPDT
Month 24 - No
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
NEI VFQ-25 Total 4.6 score @ 13wk0.5 mg
absolute change · score
No placebo or comparator arm
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
2.9 score @ 13wk0.5 mg + vPDT
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
1.7 score @ 13wk0.5 mg + vPDT
Month 3 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
NEI VFQ-25 Total 5.4 score @ 52wk0.5 mg
absolute change · score
No placebo or comparator arm
Month 12 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
6.4 score @ 52wk0.5 mg + vPDT
Month 12 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
2.7 score @ 52wk0.5 mg + vPDT
Month 12 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
NEI VFQ-25 Total 4.8 score @ 104wk0.5 mg
absolute change · score
No placebo or comparator arm
Month 24 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence
show 2 more results
5.5 score @ 104wk0.5 mg + vPDT
Month 24 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination
2.8 score @ 104wk0.5 mg + vPDT
Month 24 - Change from Baseline
NCT01846273 · Phase 4 · registry result, not featured evidence · combination

+ 44 further endpoints in the CSV export.

Wet Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Wet Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Ranibizumab · Lucentis

Marketed by Roche and partners

Approved in Wet Age-Related Macular Degenerationantibody fragment
Partial signal

NCT00095433 · Phase 3 · completed

The study was explicitly an extension of prior ranibizumab treatment studies (FVF1770g, FVF2128g, or FVF2425g), but it was open-label, had no comparator arm, and enrolled 100 participants. Because no results or primary endpoint findings are posted, whether the primary endpoint was met is unknown.

No aligned efficacy figure on record for this race.

Results for Wet Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Aflibercept: 11 of 11 rows · Ranibizumab: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAflibercept
Rows use multiple source trials
Ranibizumab
Rows use multiple source trials
BCVA Change Letters
absolute change · Letters correctly read
No placebo or comparator arm
-2.1 Letters correctly read @ 104wk2 mg intravitreala,b,c,d,e
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.4 Letters correctly read @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
1 Letters correctly read @ 52wk0.5 mga,b,c,d,e
NCT01780935 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.1 Letters correctly read @ 52wk0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
BCVA Change Letters
absolute change · letters
No placebo or comparator arm
9 letters @ 52wka,c,d
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more dose
8.4 letters @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
12.3 letters @ 52wk0.5 mg monthlya,c,d
NCT01775124 · Phase 4 · registry result, not featured evidence
show 1 more dose
9.6 letters @ 52wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
BCVA Gain 15 Letters
absolute value · percentage points
37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4a,f,c,d,g
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more doses
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
39.1% (n=151) vs 34% (n=147) Lucentis @ 24wk1.5 mg / 0.5 mga,f,c,d,g
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
33.3% (n=147) vs 34% (n=147) Lucentis @ 24wk0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
CRT Change Microns
absolute change · m
No placebo or comparator arm
-134.4 m @ 52wka,c,d
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more dose
-126.1 m @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
-147.1 m @ 52wka,c,d
NCT01972789 · Phase 4 · registry result, not featured evidence
show 1 more dose
-125.6 m @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
Lesion Area Change Mm2
absolute change · mm
-4.7 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,h,c,d,i
NCT02713204 · Phase 2 · registry result, not featured evidence
show 2 more doses
-3.9 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
-5.3 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
-0.6382 vs -1.1814 Lucentis mm @ 48wkh,c,d,i
NCT02611778 · Phase 3 · registry result, not featured evidence
NEI VFQ-25 Total
absolute change · score
6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4a,c,d,j
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more doses
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.3 vs 3.75 Lucentis score @ 48wkc,d,j
NCT02611778 · Phase 3 · registry result, not featured evidence
no IRF and no SRF Center Subfield
event count · % of participants
No placebo or comparator arm
50.9% (n=53) @ 16wk*k,c,d,l
NCT04126317 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
37.2% (n=172) @ 104wk*a,k,c,d,l
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 64 Participants as posted
show 1 more dose
32.4% (n=173) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted
Dropout rate
3.6%2.0mg Q4m
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
10.7%n
NCT02161575 · Phase 4 · registry result, not featured evidence
show 28 more results
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
23%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
17.1%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
17.3%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
6.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
6%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
5%
NCT02611778 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
4.4%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
6.2%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
5.5%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
5.8%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
8.3%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
20%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
25%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
10.7%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.3%1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
3.4%0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
2.3%700 µg
NCT00775411 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination
16.7%
NCT00517010 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
1%2.0mg Q4m
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
1.9%n
NCT02161575 · Phase 4 · registry result, not featured evidence
show 28 more results
—Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
6.3%Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
2.3%Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
1.2%Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
3%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
3%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
0.4%
NCT02611778 · Phase 3 · registry result, not featured evidence
0.6%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0.7%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
—0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
—4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—700 µg
NCT00775411 · Phase 2 · registry result, not featured evidence · combination
—
NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT00517010 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
23%2.0mg Q4m
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
10%n
NCT02161575 · Phase 4 · registry result, not featured evidence
show 28 more results
33.5%Intensive
NCT01972789 · Phase 4 · registry result, not featured evidence
—Intensive Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
33.3%Relaxed
NCT01972789 · Phase 4 · registry result, not featured evidence
—Relaxed Retinal Fluid Regimen
NCT01972789 · Phase 4 · registry result, not featured evidence
6.7%0.5 mg
NCT01986907 · Phase 4 · registry result, not featured evidence
—Ranibizumab
NCT01986907 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
14.5%0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
8%
NCT02611778 · Phase 3 · registry result, not featured evidence
9%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
13.4%0.5 mg
NCT01780935 · Phase 3 · registry result, not featured evidence
20.7%0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
24.1%0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
19.9%2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
19.7%2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
0%0.5 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
8%0.5 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg monthly
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0%2.0 mg PRN
NCT00764738 · Phase 2/3 · registry result, not featured evidence
14.3%4.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
3.2%2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
—0.3 mg / 0.5 mg
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
6.6%high dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
9.4%low dose
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
13.6%700 µg
NCT00775411 · Phase 2 · registry result, not featured evidence · combination
10%
NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT00517010 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
2.0mg Q4m
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 24 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
n
nasopharyngitis 9%
cough 7%
lower respiratory tract infection 7%
NCT02161575 · Phase 4 · registry result, not featured evidence
show 20 more results
eye pain 16.2%
influenza 15%
influenza(non-ocular) 15%
NCT01972789 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.7%
nasopharyngitis(non-ocular) 16.7%
eye pain 13.8%
NCT01972789 · Phase 4 · registry result, not featured evidence
0.5 mg
neovascular age-related macular degeneration 3.6%
influenza 1.6%
conjunctival haemorrhage 1.4%
NCT01986907 · Phase 4 · registry result, not featured evidence
0.5 mg monthly
nasopharyngitis 14.5%
conjunctival haemorrhage 12.7%
upper respiratory tract infection 8.4%
NCT01775124 · Phase 4 · registry result, not featured evidence
0.5 mg PRN
nasopharyngitis 10.8%
conjunctival haemorrhage 7.2%
intraocular pressure increased 7.2%
NCT01775124 · Phase 4 · registry result, not featured evidence
neovascular age-related macular degeneration 8%
conjunctival haemorrhage 5.9%
nasopharyngitis 5%
NCT02611778 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 7.2%
conjunctival haemorrhage (study eye) 5.7%
hypertension 5.4%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg
intraocular pressure increased (study eye) 6.3%
hypertension 4.5%
influenza 4.5%
NCT01780935 · Phase 3 · registry result, not featured evidence
0.5 mg as-needed (PRN)
conjunctival haemorrhage 17.5%
sinusitis 9.8%
hypertension 7.6%
NCT00891735 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
conjunctival haemorrhage 23%
vitreous floaters 9.5%
vitreous detachment 8%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg as-needed (PRN)
conjunctival haemorrhage 15.1%
vitreous detachment 9.9%
eye pain 8.5%
NCT00891735 · Phase 3 · registry result, not featured evidence
2.0 mg monthly
conjunctival haemorrhage 18.6%
eye pain 9.1%
vitreous detachment 8.8%
NCT00891735 · Phase 3 · registry result, not featured evidence
0.5 mg monthly
injection site irritation 4.5%
corneal abrasion 0%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
0.5 mg PRN
corneal abrasion 4%
injection site irritation 4%
NCT00764738 · Phase 2/3 · registry result, not featured evidence
4.0 mg
conjunctival hyperaemia 14.3% (placebo 0%)
eyelid oedema 10.7% (placebo 0%)
retinal haemorrhage 10.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
2.0 mg
eye pain 12.9% (placebo 0%)
conjunctival haemorrhage 9.7% (placebo 11.8%)
retinal haemorrhage 9.7% (placebo 0%)
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
high dose
conjunctival hemorrhage 33.6%
punctate keratitis 9.9%
conjunctival hyperemia 8.6%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
low dose
conjunctival hemorrhage 22.8%
punctate keratitis 12.8%
eye pain 6.7%
NCT01089517 · Phase 2 · registry result, not featured evidence · combination
700 µg
conjunctival haemorrhage 13.6%
intraocular pressure increased 6.8%
NCT00775411 · Phase 2 · registry result, not featured evidence · combination
ocular hypertension 70%
subconjunctival hemorrhage 50%
posterior vitreous detachment 20%
NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 104 weeks versus 52 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gAssessment timepoints differ: 52 weeks versus 24 weeks.
  8. hTrial phases differ: Phase 2 versus Phase 3.
  9. iAssessment timepoints differ: 36 weeks versus 48 weeks.
  10. jAssessment timepoints differ: 52 weeks versus 48 weeks.
  11. kTrial phases differ: Phase 2 versus Phase 4.
  12. lAssessment timepoints differ: 16 weeks versus 104 weeks.
  13. mPopulation comparability has not been reviewed for 21 of these studies.
  14. nPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 6 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Loss Less Than 15 Letters 93.4% (n=106) @ 104wk2 mg intravitreal
responder rate · % of participants
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 3 more results
96.2% (n=104) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=106) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=104) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Change Letters 7.8 Letters @ 52wk2 mg intravitreal
absolute change · Letters
No placebo or comparator arm
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
10.2 Letters @ 52wk2 mg intravitreal
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Change Letters 4.3 Letters @ 104wk2 mg intravitreal
absolute change · Letters
No placebo or comparator arm
From baseline to Week 104
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 Letters @ 104wk2 mg intravitreal
From baseline to Week 104
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Gain 15 Letters 19.8% (n=106) @ 52wk2 mg intravitreal
responder rate · % of participants
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 12 more results
27.9% (n=104) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
18.9% (n=106) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
22.1% (n=104) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.8% (n=31) @ 12wk2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
16.1% (n=31) @ 12wk2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
18.8% (n=32) @ 12wk0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
21.9% (n=32) @ 12wk0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
9.7% (n=31) @ 12wk4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
32.5% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
30.9% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
25.8% (n=151) @ 52wk
NCT01722045 · Phase 4 · registry result, not featured evidence
22.5% (n=151) @ 100wk
NCT01722045 · Phase 4 · registry result, not featured evidence
BCVA Maintained Vision 94% (n=167) @ 52wk2 mg every 8 weeks
responder rate · % of participants
No placebo or comparator arm
NCT02540954 · Phase 3 · registry result, not featured evidence
show 3 more results
96.7% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
95.9% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
95.2% (n=165) @ 52wk
NCT02540954 · Phase 3 · registry result, not featured evidence
no IRF and no SRF Center Subfield 68.3% (n=123) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more result
69.1% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
Dry Retina Resolution 53% (n=151) @ 52wk
responder rate · % of participants
No placebo or comparator arm
Week 52: Dry
NCT01722045 · Phase 4 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

Ranibizumab

Dry Retina Resolution 0% (n=100) @ 25.7wk
event count · % of participants
No placebo or comparator arm
Day 180 · Yes, Definitive
NCT02161575 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
BCVA Change Letters 3.3 Letters0.5 mg monthly
absolute change · Letters
No placebo or comparator arm
NCT01775124 · Phase 4 · registry result, not featured evidence
show 11 more results
1.7 Letters0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
3.7 Letters0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
2.2 Letters0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
10.1 Letters @ 52wk0.5 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
8.2 Letters @ 52wk0.5 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
9.2 Letters @ 52wk2.0 mg monthly
NCT00891735 · Phase 3 · registry result, not featured evidence
8.6 Letters @ 52wk2.0 mg as-needed (PRN)
NCT00891735 · Phase 3 · registry result, not featured evidence
3.2 Letters @ 104wk
NCT01972789 · Phase 4 · registry result, not featured evidence
2.5 Letters @ 104wk
NCT01972789 · Phase 4 · registry result, not featured evidence
4.6 Letters @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
3.9 Letters @ 52wk
NCT01972789 · Phase 4 · registry result, not featured evidence
BCVA Gain 15 Letters 16.9% (n=172) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 29 Participants as posted
show 3 more results
13.9% (n=173) @ 52wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 24 Participants as posted
14.5% (n=172) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 25 Participants as posted
13.9% (n=173) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 24 Participants as posted
BCVA Loss Less Than 15 Letters 82.6% (n=172) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 142 Participants as posted
show 3 more results
81.5% (n=173) @ 52wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 141 Participants as posted
75% (n=172) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 129 Participants as posted
76.3% (n=173) @ 104wk*
NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 132 Participants as posted
BCVA Change Letters 10.1 Letters @ 52wk0.5 mg monthly
absolute change · Letters
No placebo or comparator arm
Average Month 1 through month 12
NCT01775124 · Phase 4 · registry result, not featured evidence
show 1 more result
8.1 Letters @ 52wk0.5 mg PRN
Average Month 1 through month 12
NCT01775124 · Phase 4 · registry result, not featured evidence
BCVA Change Letters 11 Letters @ 104wk0.5 mg monthly
absolute change · Letters
No placebo or comparator arm
Average Month 1 through month 24
NCT01775124 · Phase 4 · registry result, not featured evidence
show 1 more result
8.9 Letters @ 104wk0.5 mg PRN
Average Month 1 through month 24
NCT01775124 · Phase 4 · registry result, not featured evidence
BCVA Loss 15 Letters 99.4% (n=165) @ 4.33wk0.5 mg monthly
event count · % of participants
No placebo or comparator arm
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 164 Patients as posted
show 47 more results
98.2% (n=166) @ 4.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 163 Patients as posted
98.8% (n=165) @ 8.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 163 Patients as posted
97.6% (n=166) @ 8.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
97% (n=165) @ 13wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
97.6% (n=166) @ 13wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
97.6% (n=165) @ 17.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
97.6% (n=166) @ 17.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
97% (n=165) @ 21.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
96.4% (n=166) @ 21.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
98.2% (n=165) @ 26wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
96.4% (n=166) @ 26wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
98.2% (n=165) @ 30.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
95.2% (n=166) @ 30.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 158 Patients as posted
98.2% (n=165) @ 34.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
95.8% (n=166) @ 34.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 159 Patients as posted
98.8% (n=165) @ 39wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 163 Patients as posted
95.8% (n=166) @ 39wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 159 Patients as posted
98.2% (n=165) @ 43.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
97% (n=166) @ 43.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
98.2% (n=165) @ 47.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
97% (n=166) @ 47.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
98.2% (n=165) @ 52wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
96.4% (n=166) @ 52wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
98.2% (n=165) @ 56.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
94.6% (n=166) @ 56.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 157 Patients as posted
97.6% (n=165) @ 60.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
95.2% (n=166) @ 60.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 158 Patients as posted
98.2% (n=165) @ 65wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
95.8% (n=166) @ 65wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 159 Patients as posted
98.8% (n=165) @ 69.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 163 Patients as posted
95.8% (n=166) @ 69.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 159 Patients as posted
97.6% (n=165) @ 73.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
94.6% (n=166) @ 73.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 157 Patients as posted
96.4% (n=165) @ 78wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 159 Patients as posted
94.6% (n=166) @ 78wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 157 Patients as posted
98.2% (n=165) @ 82.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 162 Patients as posted
93.4% (n=166) @ 82.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 155 Patients as posted
97.6% (n=165) @ 86.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 161 Patients as posted
93.4% (n=166) @ 86.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 155 Patients as posted
95.2% (n=165) @ 91wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 157 Patients as posted
93.4% (n=166) @ 91wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 155 Patients as posted
97% (n=165) @ 95.33wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 160 Patients as posted
92.8% (n=166) @ 95.33wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 154 Patients as posted
95.8% (n=165) @ 99.67wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 158 Patients as posted
92.2% (n=166) @ 99.67wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 153 Patients as posted
95.8% (n=165) @ 104wk*0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 158 Patients as posted
92.2% (n=166) @ 104wk*0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence · converted to % from 153 Patients as posted
CST Change Microns -112.8 microns @ 4.33wk0.5 mg monthly
absolute change · microns
No placebo or comparator arm
NCT01775124 · Phase 4 · registry result, not featured evidence
show 47 more results
-108.7 microns @ 4.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-141.1 microns @ 8.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-130.4 microns @ 8.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-141.3 microns @ 13wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-141.2 microns @ 13wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-150.4 microns @ 17.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-134.5 microns @ 17.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-155.2 microns @ 21.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-131.5 microns @ 21.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-158.6 microns @ 26wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-138.3 microns @ 26wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-156.9 microns @ 30.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-137.9 microns @ 30.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-165.4 microns @ 34.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-142.2 microns @ 34.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-165.1 microns @ 39wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-143.3 microns @ 39wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-165.9 microns @ 43.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-152.5 microns @ 43.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-166.6 microns @ 47.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-152.5 microns @ 47.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-166.5 microns @ 52wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-155.7 microns @ 52wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-160.3 microns @ 56.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-151.4 microns @ 56.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-159.9 microns @ 60.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-153.2 microns @ 60.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-156.9 microns @ 65wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-158.1 microns @ 65wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-155.9 microns @ 69.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-158.1 microns @ 69.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-161.8 microns @ 73.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-156.8 microns @ 73.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-159.5 microns @ 78wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-156.7 microns @ 78wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-158.5 microns @ 82.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-154.8 microns @ 82.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-157.6 microns @ 86.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-152.1 microns @ 86.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-155.2 microns @ 91wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-151.9 microns @ 91wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-156.8 microns @ 95.33wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-146.5 microns @ 95.33wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-159.4 microns @ 99.67wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-148.3 microns @ 99.67wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
-167.7 microns @ 104wk0.5 mg monthly
NCT01775124 · Phase 4 · registry result, not featured evidence
-153.2 microns @ 104wk0.5 mg PRN
NCT01775124 · Phase 4 · registry result, not featured evidence
BCVA Change Letters -1.7 vs 4.35 placebo letters @ 24wk4.0 mg
absolute change · letters
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
show 5 more results
0.87 vs 4.35 placebo letters @ 24wk2.0 mg
NCT03211234 · Phase 2 · registry result, not featured evidence · combination
5.1 vs 5.6 Lucentis letters @ 8wk
NCT02611778 · Phase 3 · registry result, not featured evidence
6.9 vs 7.1 Lucentis letters @ 24wk
NCT02611778 · Phase 3 · registry result, not featured evidence
7.8 vs 8 Lucentis letters @ 48wk
NCT02611778 · Phase 3 · registry result, not featured evidence
7.8 vs 7.9 Lucentis letters @ 52wk
NCT02611778 · Phase 3 · registry result, not featured evidence
Foveal Center Point Thickness Change Microns -203.94 vs -205.45 Lucentis m @ 24wk
absolute change · m
NCT02611778 · Phase 3 · registry result, not featured evidence
show 1 more result
-213.26 vs -211.02 Lucentis m @ 48wk
NCT02611778 · Phase 3 · registry result, not featured evidence
CST Change Microns -180.37 vs -181.63 Lucentis m @ 24wk
absolute change · m
NCT02611778 · Phase 3 · registry result, not featured evidence
show 1 more result
-182.85 vs -190.75 Lucentis m @ 48wk
NCT02611778 · Phase 3 · registry result, not featured evidence
Active CNV Leakage 52% (n=221) vs 50.7% (n=219) Lucentis @ 24wk
event count · % of participants
CNV leakage
NCT02611778 · Phase 3 · registry result, not featured evidence · converted to % from 115 Participants as posted
show 1 more result
56.4% (n=211) vs 58.7% (n=196) Lucentis @ 48wk*
CNV leakage
NCT02611778 · Phase 3 · registry result, not featured evidence · converted to % from 119 Participants as posted

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Ranibizumab's landscape